within Pharmacolibrary.Drugs.ATC.N;

model N02CA07
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.1,
    Cl             = 0.0011666666666666668,
    adminDuration  = 600,
    adminMass      = 0.2 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.13,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005333333333333334,
    Tlag           = 600,            
    Vdp             = 0.25,
    k12             = 90,
    k21             = 90
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N02CA07</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Lisuride is an ergot derivative and a dopamine receptor agonist, primarily used in the past for the treatment of Parkinson's disease and hyperprolactinemia. Its use today is limited and it is not widely approved or available for clinical use in many countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after a single oral dose.</p><h4>References</h4><ol><li><p>Hümpel, M, et al., &amp; Pommerenke, G (1984). The pharmacokinetics and biotransformation of 14C-lisuride hydrogen maleate in rhesus monkey and in man. <i>European journal of drug metabolism and pharmacokinetics</i> 9(4) 347–357. DOI:<a href=&quot;https://doi.org/10.1007/BF03189685&quot;>10.1007/BF03189685</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6532807/&quot;>https://pubmed.ncbi.nlm.nih.gov/6532807</a></p></li><li><p>Burns, RS, et al., &amp; Calne, DB (1984). Disposition of oral lisuride in Parkinson&#x27;s disease. <i>Clinical pharmacology and therapeutics</i> 35(4) 548–556. DOI:<a href=&quot;https://doi.org/10.1038/clpt.1984.76&quot;>10.1038/clpt.1984.76</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6705456/&quot;>https://pubmed.ncbi.nlm.nih.gov/6705456</a></p></li><li><p>Pirtošek, Z (2011). Myths and realities of continuous dopaminergic stimulation. <i>Psychiatria Danubina</i> 23(1) 80–83. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21448103/&quot;>https://pubmed.ncbi.nlm.nih.gov/21448103</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N02CA07;
